MUSCLE

Abcuro Appoints Mark Pruzanski, M.D., as Chairman of its Board of Directors

Retrieved on: 
수요일, 12월 6, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Acquisition, Investment company, Intercept Pharmaceuticals, PBC, MUSCLE, Intercept, BIO, Autoimmune disease, Obesity, Therapy, Chronic liver disease, Eli Lilly and Company, Cancer, Trial of the century, Johns Hopkins University, Biotechnology Innovation Organization, NASH, NK, Pharmaceutical industry

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Mark Pruzanski, M.D., as Chairman of its Board of Directors.

Key Points: 
  • Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Mark Pruzanski, M.D., as Chairman of its Board of Directors.
  • Dr. Pruzanski brings more than 30 years of experience as a life sciences executive, entrepreneur and investor.
  • “We are thrilled to welcome Mark as the Chairman of the Board during a pivotal stage for Abcuro as we continue to advance our registrational Phase 2/3 MUSCLE clinical study for the treatment of inclusion body myositis,” said Alex Martin, Chief Executive Officer of Abcuro.
  • “Mark is a biotech leader with a proven record in bringing innovative new medicines to market for patient populations with unmet medical needs.

Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body Myositis

Retrieved on: 
월요일, 11월 13, 2023
Health, Clinical Trials, General Health, Research, Science, Biotechnology, MUSCLE, Clinical trial, IBM, Trial of the century, Safety, Patient, DSMB, Part, NK, Cancer, Data monitoring committee, Pharmaceutical industry

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced initiation of Part B of the registrational Phase 2/3 MUSCLE clinical study, an ongoing clinical trial of ulviprubart (ABC008) for the treatment of inclusion body myositis (IBM).

Key Points: 
  • Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced initiation of Part B of the registrational Phase 2/3 MUSCLE clinical study, an ongoing clinical trial of ulviprubart (ABC008) for the treatment of inclusion body myositis (IBM).
  • “Advancing to Part B of the Phase 2/3 MUSCLE clinical trial, combined with the positive DSMB review of the data to date, is an important milestone for both Abcuro and IBM patients.
  • The Phase 2/3 MUSCLE clinical trial ( NCT05721573 ) is a randomized, double-blind, placebo-controlled, parallel multicenter trial evaluating ulviprubart (ABC008) in patients with IBM.
  • The three-part, registrational Phase 2/3 clinical trial will enroll more than 200 patients across 30 global sites.

8 Track Entertainment Signs Winning USAC Racecar Driver Taylor Ferns for Management Representation

Retrieved on: 
금요일, 7월 29, 2022
Goal, Wayne State University Law School, Wayne State University, Grammy Awards, University of Texas at Austin Department of Radio–Television–Film, Dongbei University of Finance and Economics, Awareness, Grand Valley State University, Intelligence, 2018 USAC Silver Crown Series, Car, 1981–82 USAC Championship Car season, Female, Sport, Graduate School of Economics, Finance, and Management, Lucas Oil, Partnership, Burning at Both Ends, The Sam Bernstein Law Firm, MUSCLE, USAC, Music, De Selby, The Only One, Silver, ASCAP, Track, MBA, Wayne, Fern, BBA, Entertainment management, No, Woman, Publishing, Winchester Speedway, Economics, Berlin Raceway, NHRA, Management, Entertainment

MUSCLE SHOALS, Ala., July 29, 2022 /PRNewswire/ -- Record-setting racecar driver, Taylor Ferns, has signed with 8 Track Entertainment for exclusive management representation, it was announced today by 8 Track's co-founding partners Jeff Goodwin, V.P.

Key Points: 
  • MUSCLE SHOALS, Ala., July 29, 2022 /PRNewswire/ -- Record-setting racecar driver, Taylor Ferns, has signed with 8 Track Entertainment for exclusive management representation, it was announced today by 8 Track's co-founding partners Jeff Goodwin, V.P.
  • 8 Track'sSports Management division will be actively pursuing opportunities for Ferns to help increase brand awareness for a variety of companies.
  • "I am really excited to work with the 8 Track Entertainment group and embark on this journey with them.
  • A multi-faceted global entertainment company, 8 Track includes Sports and Entertainment Management, Music Production and Publishing, and a full-service TV/Film division.

Creators of Muscle Milk Launch New Hemp Infused Sports Nutrition Brand GYM WEED in U.S. Market

Retrieved on: 
수요일, 6월 22, 2022
Retail, Specialty, Food, Beverage, Industry, Athlete, Drupe, Europa Sports Park, Electrolyte, Energy, MUSCLE, The Non-GMO Project, Multimedia, Friends, Agriculture

GYM WEED , a hemp infused energy drink, officially launched today in the U.S. market with three unique flavors: Pear Pineapple, Stone Fruit and Tropical Berry.

Key Points: 
  • GYM WEED , a hemp infused energy drink, officially launched today in the U.S. market with three unique flavors: Pear Pineapple, Stone Fruit and Tropical Berry.
  • GYM WEED provides balanced energy without the jittery, anxious feeling typically associated with energy drinks.
  • View the full release here: https://www.businesswire.com/news/home/20220622005787/en/
    Hemp infused energy drink GYM WEED launched with three unique flavors: Stone Fruit, Pear Pineapple and Tropical Berry.
  • Both will be producing branded content as well as many more exciting things to come with GYM WEED.

Innophys Releases "MUSCLE SUIT Every" in Poland, Denmark and 3 Baltic States

Retrieved on: 
월요일, 3월 7, 2022
Contract, Baltic states, Certification, Tokyo University of Science, MUSCLE, CE, Union, Medical device, EU

TOKYO, March 7, 2022 /PRNewswire/ -- Innophys Co., Ltd. (hereinafter "Innophys"), a venture company affiliated with Tokyo University of Science, released wearable work-assisting robotic suit "MUSCLE SUIT Every" in five member countries of the European Union (EU) -- Poland, Denmark and the three Baltic states of Estonia, Latvia and Lithuania -- on March 1.

Key Points: 
  • TOKYO, March 7, 2022 /PRNewswire/ -- Innophys Co., Ltd. (hereinafter "Innophys"), a venture company affiliated with Tokyo University of Science, released wearable work-assisting robotic suit "MUSCLE SUIT Every" in five member countries of the European Union (EU) -- Poland, Denmark and the three Baltic states of Estonia, Latvia and Lithuania -- on March 1.
  • The move, which is part of the company's efforts to promote sales of the "MUSCLE SUIT" series overseas, particularly in EU member countries, has brought the number of EU countries where Innophys operates to nine.
  • The firm has already advanced into France, Spain, Italy and Sweden by signing contracts with local sales agents since the robotic suit obtained CE certification in December 2020.
  • The company is determined to accelerate its business activities in EU member countries.

Innophys MUSCLE SUIT Exhibition at CES 2022

Retrieved on: 
월요일, 12월 27, 2021
Nursing, Las Vegas Convention Center, Compressed air, Time, Exhibition, Water, CES, Arm, LVCC, MUSCLE, Lifting, Agriculture, Weather, Fatigue, Research, Multimedia, Electricity, Nightclub

TOKYO, Dec. 26, 2021 /PRNewswire/ -- Innophys Co., Ltd.(Shinjuku-ku, Tokyo, Representative:Daigo Orihara,hereafter "Innophys")will exhibit at CES 2022 in Las Vegas, from Wednesday, January 5 to Saturday, January 8, 2022.

Key Points: 
  • TOKYO, Dec. 26, 2021 /PRNewswire/ -- Innophys Co., Ltd.(Shinjuku-ku, Tokyo, Representative:Daigo Orihara,hereafter "Innophys")will exhibit at CES 2022 in Las Vegas, from Wednesday, January 5 to Saturday, January 8, 2022.
  • At this major event, Innophys will exhibit the MUSCLE SUIT Every with waist support and the MUSCLE SUIT GS-ARM with support for work involving raising of the arms.
  • As Innophys is moving forward with a full-scale entry into the North American market, this will be the firm's first U.S. exhibition.
  • MUSCLE SUIT Every is an assist suit that reduces the burden on the waist anytime a worker must maintain a half-sitting posture, whether lifting people or heavy objects.